ELECO PUBLIC LIMITED COMPANY

Board/Management Information • Jan 28, 2020

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0669B

UDG Healthcare Public Limited Co.

28 January 2020

UDG Healthcare plc

Board Appointment and Directorate Changes

28 January 2020: UDG Healthcare plc (the "Company"), a leading international healthcare services provider, is pleased to announce the appointment of Ms Liz Shanahan as a non-executive director of the Company with effect from 1 February 2020. The Company also announces changes to the composition of one of its Board Committees, as outlined below.

Board Appointment

Liz is a life sciences entrepreneur with extensive experience advising leading global pharmaceutical and healthcare organisations on their communications. Until 2014, she was Global Head of Healthcare & Lifesciences at the NYSE-listed management consultancy, FTI Consulting Inc., who had in 2007 acquired the communications business, Santé Communications, which she had founded in 1995. She is currently a Trustee of CW+, the charitable arm of Chelsea & Westminster Foundation Trust Hospital in London. She is also a member of the organisation's Innovations Advisory Board.

Liz has a degree in Computer Programming & Maths from University College Cork, and she is an alumnus of the University of Virginia, Darden School of Business.

Directorate Change - Risk, Investment & Financing Committee

As a result of the retirement from the Board of Mr Chris Brinsmead at the end of today's Annual General Meeting (the "AGM"), the Company hereby announces that Mr Shane Cooke will assume the role of Chair of the Risk, Investment and Financing Committee, and that Mr Erik van Snippenberg has also been appointed as a member of this Committee, in each case with immediate effect following the conclusion of the AGM.

Commenting on the Board appointment, Peter Gray, Chairman of UDG Healthcare plc, said: "We're delighted to welcome Liz, who brings extensive healthcare communications experience to the Board. This combined with her entrepreneurial, M&A and professional services expertise and her insights into healthcare technology developments will inform the continued development of the Group."

This announcement is made in accordance with Listing Rule 9.6.11.

No further information to be disclosed pursuant to Listing Rule 9.6.13.

For further information, please contact:

UDG Healthcare plc

Damien Moynagh

General Counsel & Company Secretary

+353 (1) 468 9000

Business / Financial media:

Powerscourt

Lisa Kavanagh / Jack Hickey

Tel: + 44-207-250-1446

udghealthcare@powerscourt-group.com

Ends.

About UDG Healthcare plc

UDG Healthcare plc (LON: UDG) is a leading international partner of choice delivering advisory, communication, commercial, clinical and packaging services to the healthcare industry, employing 8,700 people with operations in 26 countries and delivering services in over 50 countries.

UDG Healthcare plc operates across two divisions: Ashfield and Sharp.

Ashfield - Ashfield is a global leader in commercialisation services for the pharmaceutical and healthcare industry, operating across three broad areas of activity: advisory, communications and commercial & clinical services. It focuses on supporting healthcare professionals and patients at all stages of the product life cycle. The division provides field and contact centre sales teams, healthcare communications, patient support, audit, advisory, medical information and event management services to over 300 healthcare companies.

Sharp - Sharp is a global leader in contract commercial packaging and clinical trial packaging services for the pharmaceutical and biotechnology industries, operating from state-of-the-art facilities in the US and Europe. 

The company is listed on the London Stock Exchange and is a constituent of the FTSE 250.

For more information, please go to: www.udghealthcare.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOABRMRTMTBTBAM